Blackfoot disease and arsenic: A never-ending story

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 23, Issue 1, 2005, Pages 55-74

  Tseng, Chin Hsiao ^a,b,c,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Atherogenicity; Blackfoot disease; Inorganic arsenic; Peripheral vascular disease; Water pollutant

Indexed keywords

ARSENIC; CARDIOVASCULAR SYSTEM; COAGULATION; DIAGNOSIS; EPIDEMIOLOGY; MUSCLE; OXIDATION; PATHOLOGY;

BLACKFOOT DISEASE (BFD); ENDEMIC PERIPHERAL VASCULAR DISEASES; ETIOLOGY; PATHOGENESIS;

DISEASE CONTROL;

ARSENIC; CACODYLIC ACID; DNA; HUMIC ACID; LOW DENSITY LIPOPROTEIN; METHANEARSONIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RNA;

ANIMAL MODEL; ATHEROSCLEROSIS; BLACKFOOT DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; GANGRENE; GENOTOXICITY; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; POLLUTANT; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; WATER POLLUTION;

ARSENIC; ARSENIC POISONING; HUMANS; LEG; PERIPHERAL VASCULAR DISEASES; TAIWAN; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

ANIMALIA; MELAMPODIUM;

EID: 17144420169     PISSN: 10590501     EISSN: None     Source Type: Journal    
DOI: 10.1081/GNC-200051860     Document Type: Review

References (92)

1. Tseng WP. Blackfoot disease in Taiwan: A 30-year follow-up study. Angiology 1989;40:547-558.
2. Tseng CH. An overview on peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Angiology 2002;53:529-537.
3. Yeh S, How SW. A pathological study on the blackfoot disease in Taiwan. Reports, Institute of Pathology, National Taiwan University 1963;14:25-73.
4. Kuo TL. Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Reports of Institute of Pathology, Taipei, Taiwan: National Taiwan University College of Medicine 1964;20:7-13.
5. Chen KP, Wu HY, Wu TC. Epidemiologic studies on blackfoot disease in Taiwan: III. Physicochemical characteristics of drinking water in endemic blackfoot disease areas. Memoirs College Med Natl Taiwan Univ 1962;8:115-129.
6. Lu FJ, Tsai MH, Ling KH. Studies on fluorescent compounds in drinking water of areas endemic for blackfoot disease. 3. Isolation and identification of fluorescent compounds. J Formosan Med Assoc 1978;77:68-76.
7. Tseng CH, Chong CK, Chen CJ, Tai TY. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis 1996;20:125-133.
8. Tseng CH, Chong CK, Chen CJ, Tai TY. Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. Angiology 1997;48:321-335.
9. Tseng CH, Tai TY, Lin BJ, Chen CJ. Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot disease-hyperendemic villages in Taiwan. Int J Microcirc 1995;5:21-27.
10. Tseng CH, Chen CJ, Lin BJ, Tai TY. Abnormal response of ankle pressure after exercise in seemingly normal subjects living in blackfoot disease-hyperendemic villages in Taiwan. Vasc Surg 1994;28:607-617.
11. Yeh SJ, Wu CT, Yang CY. Neutron activated analysis of blackfoot disease related specimens: (I) Trace elements in serum, urine, hair and nail samples. Blackfoot Dis Res Rep 1983;16:1-21.
12. Yeh SJ, Yang MH. Preliminary report on trace foot disease endemic area and in biopsy samples of blackfoot disease patients. Blackfoot Dis Res Rep 1980;8:22-28.
13. Smith AH, Smith MM. Arsenic drinking water regulations in developing countries with extensive exposure. Toxicology 2004;198:39-44.
14. Lo MC, Hsen YC, Lin BK. Arsenic content of underground water in Taiwan: Second report, Taichung, Taiwan: Taiwan Provincial Institute of Environmental Sanitation. 1977;1-21.
15. Lo MC. The arsenic content of farm products and fishes in areas where high arsenic well water was used for agriculture and pisciculture. Blackfoot Dis Res Rep 1978;6:28-46.
16. Blackwell RQ. Estimated total arsenic ingested by residents in the endemic blackfoot area. J Formosan Med Assoc 1961;60:1143-1144.
17. Agency for toxic substances and disease registry (ATSDR). Toxicological profile for arsenic. U.S. Environmental Protection Agency (EPA). U.S.A. 1989;5.
18. Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, Hsueh YM. Arsenic exposure, urinary arsenic speciation and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol (in press).
19. Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 1968;40:453-463.
20. Tseng CH. Abnormal current perception thresholds measured by Neurometer among residents in blackfoot disease hyperendemic villages in Taiwan. Toxicol Lett 2003;146:27-36.
21. Chang CC, Ho SC, Tsai SS, Yang CY. Ischemic heart disease mortality reduction in an arseniasis-endemic area in southwestern Taiwan after a switch in the tap-water supply system. J Toxicol Environ Health A 2004;67:1353-1361.
22. Engel RR, Hopenhaynrich C, Receveur O, Smith AH. Vascular effects of chronic arsenic exposure - A review. Epidemiol Rev 1994;16:184-209.
23. Tseng CH, Chong CK, Tseng CP, Hsueh, YM, Chiou HY, Tseng CC, Chen CJ. Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol Lett 2003;137:15-21.
24. Tseng CH. Long-term arsenic exposure and ischemic heart disease. Pathol Int 2004;54(Suppl 1):S135-S137.
25. Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol 1996;16:504-510.
26. Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 1997;28:1717-1723.
27. Bunderson M, Brooks DM, Walker DL, Rosenfeld ME, Coffin JD, Beall HD. Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol Appl Pharmacol 2004;201:32-39.
28. Simeonova PP, Luster MI. Arsenic and atherosclerosis. Toxicol Appl Pharmacol 2004;198:444-449.
29. Liou SH, Chen YH, Loh CH, Yang T, Wu TN, Chen CJ, Hsieh LL. The association between frequencies of mitomycin C-induced sister chromatid exchange and cancer risk in arseniasis. Toxicol Lett 2002;29:237-243.
30. 3) on cultured human umbilical vein endothelial cells. J Dermatol 1990;17:599-608.
31. Lee MY, Jung BI, Chung SM, Bae ON, Lee JY, Park JD, Yang JS, Lee H, Chung JH. Arsenic-induced dysfunction in relaxation of blood vessels. Environ Health Perspect 2003;111:513-517.
32. Shen MC, Tseng WP, Chen KS. Increased blood level of platelet aggregates and coagulating factors in blackfoot disease patients (in Chinese). Blackfoot Dis Res Rep 1983;15:20-28.
33. Jiang SJ, Lin TM, Wu HL, Han HS, Shi GY. Decrease of fibrinolytic activity in human endothelial cells by arsenite. Thromb Res 2002;105:55-62.
34. Lynn S, Gurr JR, Lai HT, Jan KY. NADH oxidase activation is involoved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res 2000;86:514-519.
35. Hirano S, Cui X, Li S, Kanno S, Kobayashi Y, Hayakawa T, Shraim A. Difference in uptake and toxicity of trivalent and pentavalent inorganic arsenic in rat heart microvessel endothelial cells. Arch Toxicol 2003;77:305-312.
36. Simeonova PP, Hulderman T, Harki D, Luster MI. Arsenic exposure accelerates atherogenesis in apolipoprotein e-/- mice. Environ Health Perspect 2003;111:1744-1748.
37. Akao Y, Yamada H, Nakagawa Y. Arsenic-induced apoptosis in malignant cells in vitro. Leuk Lymphoma 2000;37:53-63.
38. Lilienfeld DE. Arsenic, geographical isolates, environmental epidemiology and arteriosclerosis. Arteriosclerosis 1988;8:449-451.
39. Waalkes MP, Fox DA, States JC, Patierno SR, McCabe MJ Jr. Metals and disorders of cell accumulation: modulation of apoptosis and cell proliferation. Toxicol Sci 2000;56:255-261.
40. Mahaffey KR, Capar SG, Gladen BC, Fowler BA. Concurrent exposure to lead, cadmium, and arsenic. Effects on toxicity and tissue metal concentrations in the rat. J Lab Clin Med 1981;98:463-481.
41. Levander OA. Metabolic interrelationships between arsenic and selenium. Environ Health Perspect 1977;19:159-164.
42. Pershagen G, Wall S, Taube A, Linnman L. On the interaction between occupational arsenic exposure and smoking and its relationship to lung cancer. Scand J Work Environ Health 1981;7:302-309.
43. Pershagen G, Nordberg G, Bjorkland NE. Carcinomas of the respiratory tract in hamsters given arsenic trioxide and/or benzo-a-pyrene by the pulmonary route. Environ Res 1984;37:425-432.
44. Styblo M, Thomas DJ. Selenium modifies the metabolism and toxicity of arsenic in primary rat hepatocytes. Toxicol Appl Pharmacol 2001;172:52-61.
45. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, Kuo TL, Tai TY. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 1995;25:53-60.
46. Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, Chiou HY, Hsueh YM, Hsu KH, Chen CJ. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis- hyperendemic villages in Taiwan. Environ Health Perspect 2000;108:847-851.
47. Tseng CH, Chong CK, Heng LT, Tseng CP, Tai TY. The incidence of diabetes mellitus in Taiwan. Diabetes Res Clin Pract 2000;50 (suppl 2):S61-S64.
48. Tseng CH, Tseng CP, Chiou HY, Hsueh YM, Chong CK, Chen CJ. Epidemiologic evidence of diabetogenic effect of arsenic. Toxicol Lett 2002;133:69-76.
49. Tseng CH. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol 2004;197:67-83.
50. Bunderson M, Coffin JD, Beall HD. Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: possible role in atherosclerosis. Toxicol Appl Pharmacol 2002;184:11-18.
51. Tsai SH, Liang YC, Chen L, Ho FM, Hsieh MS, Lin JK. Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor kappaB in primary and ECV304 endothelial cells. J Cell Biochem 2002;84:750-758.
52. Kumagai Y, Pi J. Molecular basis for arsenic-Induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol Appl Pharmacol 2004;198:450-457.
53. Le XC, Ma M, Cullen WR, Aposhian HV, Lu X, Zheng B. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ. Health Perspect. 2000;108:1015-1018.
54. Aposhian HV, Zheng B, Aposhian MM, Le XC, Cebrian ME, Cullen W, Zakharyan RA, Ma M, Dart RC, Cheng Z, Andrewes P, Yip L, O'Malley GF, Maiorino RM, Van Voorhies W, Healy SM, Titcomb A. DMPS-arsenic challenge test. II. Modulation of arsenic species, including monomethylarsonous acid (MMA(III)), excreted in human urine. Toxicol Appl Pharmacol 2000;165:74-83.
55. Del Razo LM, Styblo M, Cullen WR, Thomas DJ. Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 2001;174:282-293.
56. Styblo M, Serves SV, Cullen WR, Thomas DJ. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem Res Toxicol 1997;10:27-33.
57. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Vasken AH. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 2000;163:203-207.
58. Zhong CX, Mass MJ. Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. Toxicol Lett 2001;122:223-234.
59. Lin S, Del Razo LM, Styblo M, Wang C, Cullen WR, Thomas DJ. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 2001;14:305-311.
60. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, Kligerman AD. Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 2001;14:355-361.
61. Nesnow S, Roop BC, Lambert G, Kadiiska M, Mason RP, Cullen WR, Mass MJ. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol 2002;15:1627-1634.
62. Yamanaka K, Takabayashi F, Mizoi M, An Y, Hasegawa A, Okada S. Oral exposure of dimethylarsinic acid, a main metabolite of inorganic arsenics, in mice leads to an increase in 8-Oxo-2′-deoxyguanosine level, specifically in the target organs for arsenic carcinogenesis. Biochem Biophys Res Commun 2001;287:66-70.
63. Walton FS, Harmon AW, Paul DS, Drobna Z, Patel YM, Styblo M. Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetes. Toxicol Appl Pharmacol 2004;198:424-433.
64. Chen JZ, Kadlubar FF. Mitochondrial mutagenesis and oxidative stress in human prostate cancer. J Environ Sci Health C 2004;22:1-12.
65. Cheng YW, Lee H. Environmental exposure and lung cancer among nonsmokers: An example of Taiwanese female lung cancer. J Environ Sci Health C 2003;21:1-28.
66. Talaska G. Aromatic amines and human urinary bladder cancer: Exposure sources and epidemiology. J Environ Sci Health C 2003;21:29-43.
67. Fu PP, Cheng SH, Coop L, Xia Q, Gulp SJ, Tolleson WH, Warner WG, Howard PC. Photoreaction, phototoxicity, and photocarcinogenicity of retinoids. J Environ Sci Health C 2003;21:165-197.
68. Ahmed FE. Colon cancer: Prevalence, screening, gene expression and mutation, and risk factors and assessment. J Environ Sci Health C 2003;21:65-131.
69. Li K, Yu S. Economic status, smoking, occupational exposure to rubber, and lung cancer: A case-cohort study. J Environ Sci Health C 2002;20:21-28.
70. Benigni R, Giuliani A. Tumor geography of Italy and Europe: Patterns and correlations with socioeconomic variables. J Environ Sci Health C 2001;19:325-351.
71. Hansen ES. Shared risk factors for cancer and atherosclerosis: A review of epidemiological evidence. Mutat Res 1990;239:163-179.
72. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1973;70:1753-1756.
73. Hatzistamou J, Kiaris H, Ergazaki M, Spandidos DA. Loss of heterozygosity and microsatellite instability in human atherosclerotic plaque. Biochem Biophys Res Commun 1996;255:186-190.
74. Nordenson I, Beckman L. Is the genotoxic effect of arsenic mediated by oxygen free radicals? Hum Hered 1991;41:71-73.
75. Pi J, Yamauchi H, Kumagai Y, Sun G, Yoshida T, Aikawa H, Hopenhayn-Rich C, Shimojo N. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 2002;110:331-336.
76. Galle J, Heermeier K, Wanner C. Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int 1999;71(suppl):S62-S65.
77. Hsueh YM, Wu WL, Huang YL, Chiou HY, Tseng CH, Chen CJ. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis 1998;141:249-257.
78. Hunder G, Nguyen PT, Schümann K, Fichtl B. Influence of inorganic and organic arsenicals on intestinal transfer of nutrients. Res Commun Chem Pathol Pharmacol 1993;80:83-92.
79. Lu FJ, Liu TM. Fluorescent compounds in drinking water of blackfoot disease endemic areas: animal experimental model. (In Chinese with English abstract). J Formos Med Assoc 1986;85:352-358.
80. Van Duuren BL, Melchionne S, Seidman I, Pereira MA. Chronic bioassays of chlorinated humic acids in B6C3F1 mice. Environ Health Perspect 1986;69:109-117.
81. Yang HL, Tu SC, Lu FJ, Chiu HC. Plasma protein C activity is enhanced by arsenic but inhibited by fluorescent humic acid associated with blackfoot disease. Am J Hematol 1994;46:264-269.
82. Lu FJ, Irgolic KJ, Lin CW, Ling KH, Tung TC. Fluorescent compounds in drinking well water of blackfoot disease endemic areas. Ergotamine in the artesian well water. (In Chinese with English abstract). J Formos Med Assoc 1982;81:1087-1100.
83. Mak OT. Plasma prostaglandins levels as a diagnostic indicator of blackfoot disease (in Chinese). Blackfoot Disease Research Report 1990;35:16-43.
84. Hseu YC, Wang SY, Chen HY, Lu FJ, Gau RJ, Chang WC, Liu TZ, Yang HL. Humic acid induces the generation of nitric oxide in human umbilical vein endothelial cells: stimulation of nitric oxide synthase during cell injury. Free Radic Biol Med 2002;32:619-629.
85. Hseu YC, Huang HW, Wang SY, Chen HY, Lu FJ, Gau RJ, Yang HL. Humic acid induces apoptosis in human endothelial cells. Toxicol Appl Pharmacol. 2002;182:34-43.
86. Chen CH, Liu JJ, Lu FJ, Yang ML, Lee Y, Huang TS. The effect of humic acid on the adhesibility of neutrophils. Thromb Res. 2002;108:67-76.
87. Ishaque AB, Tchounwou PB, Wilson BA, Washington T. Developmental arrest in Japanese medaka (Oryzias latipes) embryos exposed to sublethal concentrations of atrazine and arsenic trioxide. J Environ Biol 2004;25:1-6.
88. Vardhanan YS, Radhakrishnan T. Acute toxicity evaluation of copper, arsenic and HCH to paddy field crab, Paratelphusa hydrodromus (Herb.). J Environ Biol 2002;23:387-392.
89. Lu FJ, Yamamura Y, Yamauchi H. Studies on fluorescent compounds in water of a well in Blackfoot disease endemic areas in Taiwan: Humic substances. J. Formosan Med. Assoc. 1988;87:66-75.
90. Naranjo-Pulido A, Romero-Schmidt H, Mendez-Rodriguez L, Acosta-Vargas B, Ortega-Rubio A. Soil arsenic contamination in the Cape Region, B.C.S., Mexico. J Environ Biol 2002;23:347-352.
91. Tseng CH. Chronic arsenic intoxication in Asia: Current perspectives. J Intern Med Taiwan 1999;10:224-229.
92. Berg M, Tran HC, Nguyen TC, Pham HV, Schertenleib R, Giger W. Arsenic contamination of groundwater and drinking water in Vietnam: a human health threat. Environ Sci Technol 2001;35:2621-2626.